EURO-CHLORHEXIDINE MOUTHWASH
Land: Canada
Taal: Engels
Bron: Health Canada
Productkenmerken
(SPC)
14-06-2023
Sommige documenten voor dit product zijn momenteel niet beschikbaar, u kunt een verzoek sturen naar onze klantenservice en we zullen u hiervan op de hoogte stellen zodra we ze kunnen verkrijgen.
Verzend verzoek.
Verzend verzoek.
Werkstoffen:
CHLORHEXIDINE GLUCONATE
Beschikbaar vanaf:
EURO-PHARM INTERNATIONAL CANADA INC
ATC-code:
A01AB03
INN (Algemene Internationale Benaming):
CHLORHEXIDINE
Dosering:
0.12%
farmaceutische vorm:
MOUTHWASH
Samenstelling:
CHLORHEXIDINE GLUCONATE 0.12%
Toedieningsweg:
BUCCAL
Eenheden in pakket:
500ML/4L
Prescription-type:
Prescription
Therapeutisch gebied:
MISCELLANEOUS ANTI-INFECTIVES
Product samenvatting:
Active ingredient group (AIG) number: 0107629007; AHFS:
Autorisatie-status:
APPROVED
Autorisatie datum:
2017-04-05
Productkenmerken
1
PRODUCT MONOGRAPH
PR
EURO-CHLORHEXIDINE
Chlorhexidine Gluconate Oral Rinse
0.12% w/v
House Standard
ANTIGINGIVITIS ORAL RINSE
EURO-PHARM INTERNATIONAL CANADA INC.
9400 BOUL. LANGELIER
MONTREAL, QUEBEC
H1P 3H8
CONTROL NUMBER: 275418
DATE OF PREPARATION:
APR 05, 2017
DATE OF
REVISION:
JUN 14, 2023
2
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
........................................................ 3
SUMMARY PRODUCT INFORMATION
.......................................................................
3
INDICATIONS AND CLINICAL USE
.............................................................................
3
CONTRAINDICATIONS
..................................................................................................
3
WARNINGS AND PRECAUTIONS
.................................................................................
4
ADVERSE REACTIONS
...................................................................................................
5
DRUG INTERACTIONS
...................................................................................................
5
DOSAGE AND ADMINISTRATION
...............................................................................
5
OVERDOSAGE
.................................................................................................................
6
ACTION AND CLINICAL PHARMACOLOGY
............................................................. 7
STORAGE AND STABILITY
...........................................................................................
8
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................. 8
PART II: SCIENTIFIC INFORMATION
................................................................................
9
PHARMACEUTICAL INFORMATION
...........................................................................
9
CLINICAL TRIALS
.........................................................................................................
10
TOXICOLOGY
..........................................................
Lees het volledige document
